Travere Therapeutics IncNASDAQ:TVTX
- LAST PRICE5.5150
- TODAY'S CHANGE (%)-0.2250 (-3.9199%)
- Bid / Lots5.5100/ 2
- Ask / Lots5.5200/ 5
- Open / Previous Close5.7800 / 5.7400
- Day Range
- 52 Week Range
- Volume206,550
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TVTX |
|---|---|---|
| 09:32 ET | 10039 | 5.73 |
| 09:34 ET | 400 | 5.7 |
| 09:36 ET | 516 | 5.73 |
| 09:38 ET | 5245 | 5.715 |
| 09:39 ET | 2600 | 5.685 |
| 09:41 ET | 4448 | 5.705 |
| 09:43 ET | 2574 | 5.7288 |
| 09:45 ET | 1600 | 5.7 |
| 09:48 ET | 6498 | 5.57 |
| 09:50 ET | 5159 | 5.64 |
| 09:52 ET | 6500 | 5.65 |
| 09:54 ET | 5532 | 5.69 |
| 09:56 ET | 5375 | 5.73 |
| 09:57 ET | 1776 | 5.77 |
| 09:59 ET | 1700 | 5.74 |
| 10:01 ET | 700 | 5.7093 |
| 10:03 ET | 800 | 5.71 |
| 10:06 ET | 800 | 5.7 |
| 10:08 ET | 356 | 5.705 |
| 10:10 ET | 600 | 5.695 |
| 10:12 ET | 200 | 5.7 |
| 10:14 ET | 600 | 5.695 |
| 10:15 ET | 2289 | 5.685 |
| 10:17 ET | 840 | 5.675 |
| 10:19 ET | 300 | 5.67 |
| 10:21 ET | 300 | 5.665 |
| 10:24 ET | 1830 | 5.655 |
| 10:26 ET | 900 | 5.6488 |
| 10:28 ET | 3147 | 5.65 |
| 10:30 ET | 2276 | 5.645 |
| 10:32 ET | 1695 | 5.655 |
| 10:33 ET | 1065 | 5.645 |
| 10:35 ET | 1433 | 5.655 |
| 10:37 ET | 3505 | 5.645 |
| 10:39 ET | 700 | 5.635 |
| 10:42 ET | 7421 | 5.62 |
| 10:44 ET | 640 | 5.61 |
| 10:46 ET | 600 | 5.61 |
| 10:48 ET | 1500 | 5.605 |
| 10:50 ET | 100 | 5.59 |
| 10:51 ET | 6877 | 5.58 |
| 10:53 ET | 10042 | 5.54 |
| 10:55 ET | 1550 | 5.5487 |
| 11:00 ET | 3231 | 5.55 |
| 11:02 ET | 2451 | 5.55 |
| 11:04 ET | 4716 | 5.525 |
| 11:06 ET | 7532 | 5.52 |
| 11:08 ET | 662 | 5.52 |
| 11:09 ET | 3418 | 5.52 |
| 11:11 ET | 7712 | 5.5391 |
| 11:13 ET | 867 | 5.54 |
| 11:15 ET | 100 | 5.545 |
| 11:20 ET | 400 | 5.54 |
| 11:22 ET | 300 | 5.53 |
| 11:24 ET | 2281 | 5.555 |
| 11:26 ET | 100 | 5.55 |
| 11:27 ET | 300 | 5.545 |
| 11:29 ET | 6806 | 5.54 |
| 11:31 ET | 1190 | 5.53 |
| 11:33 ET | 500 | 5.52 |
| 11:36 ET | 400 | 5.515 |
| 11:38 ET | 1798 | 5.52 |
| 11:40 ET | 900 | 5.52 |
| 11:42 ET | 954 | 5.52 |
| 11:44 ET | 8497 | 5.515 |
Today
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI(R) (sparsentan) for the treatment of IgA Nephropathy, from 4 hours ago by Dow Jones
4 hours ago by Dow JonesCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy, from 8 hours ago by Dow Jones
8 hours ago by Dow JonesCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI(R) (sparsentan) for the treatment of IgA Nephropathy, from 8 hours ago by Dow Jones
8 hours ago by Dow Jones
Apr 17, 2024
DJ Travere Therapeutics Price Target Maintained With a $13.00/Share by Wedbush, from 1:33PM ET on Wednesday Apr 17, 2024 by Dow Jones
1:33PM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 4, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Travere Therapeutics Inc | 436.9M | -1.1x | --- |
Avid Bioservices Inc | 422.4M | -37.6x | --- |
Entrada Therapeutics Inc | 433.1M | -50.0x | --- |
Heron Therapeutics Inc | 420.9M | -3.1x | --- |
Kamada Ltd | 292.5M | 29.4x | -22.48% |
Anika Therapeutics Inc | 377.6M | -4.6x | --- |
Company Information
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).
Contact Information
- Headquarters
- 3611 Valley Centre Dr, Suite 300SAN DIEGO, CA, United States 92130
- Phone
- 760-260-8600
- Fax
- 302-645-1280
Executives
- Independent Chairman of the Board
- Gary Lyons
- President, Chief Executive Officer, Director
- Eric Dube
- Chief Financial Officer
- Christopher Cline
- Senior Vice President, General Counsel, Corporate Secretary
- Elizabeth Reed
- Senior Vice President and Head of Research and Development
- William Rote
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $436.9M |
|---|---|
Revenue (TTM) | $145.2M |
Shares Outstanding | 76.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.68 |
EPS | $-4.98 |
Book Value | $2.66 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -267.24% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
